#IBCSG

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials | JCO P... PURPOSETo investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characte...

🚩pleased to share our latest "Genomic Characterisation and Prognostic Significance of HER2–Low, HR+, Early #Breastcancer From the BIG 1-98 and SOFT Clinical Trials" #bcsm using centrally reviewed HER2 IHC from 2 large clinical trials #IBCSG @oncoalert.bsky.social 👏
ascopubs.org/doi/10.1200/...